Treatment of Mediterranean visceral leishmaniasis

• Published in: Bulletin of the World Health Organization Vol. 73; no. 2; pp. 191 - 197
• Main Authors: GRADONI, L, BRYCESON, A, DESJEUX, P
• Format: Journal Article
• Language: English
• Published: Genève Organisation mondiale de la santé 01.01.1995; World Health Organization
• Subjects: Adolescent; Adult; Amphotericin B; Amphotericin B - therapeutic use; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antimony - therapeutic use; Antiparasitic agents; Antiprotozoal Agents - therapeutic use; Biological and medical sciences; Child; Child, Preschool; Demographic aspects; Europe - epidemiology; Evaluation; Humans; Infant; Leishmaniasis; Leishmaniasis, Visceral - drug therapy; Leishmaniasis, Visceral - epidemiology; Liposomes - therapeutic use; Medical sciences; Mediterranean Islands - epidemiology; Meglumine - therapeutic use; Organometallic Compounds - therapeutic use; Pharmacology. Drug treatments; Mediterranean Islands; Europe; Human; Immunopathology; Protozoal disease; Liposome; Parasitosis; Leishmaniasis; Zoonosis; Epidemiology; Recommendation; Infection; Chemotherapy; Treatment; Polyenic compound; Dosage form; Mediterranean region; Public health; Viscus
• ISSN: 0042-9686; 1564-0604

Up-to-date information is given on the epidemiological situation of zoonotic visceral leishmaniasis (ZVL) in nine Mediterranean countries, and on drug regimens adopted in the management of ZVL patients in each country. Results of experimental and clinical trials on the efficacy and tolerability of liposomal amphotericin B in laboratory animals and in patients with ZVL are presented, as well as conclusions and recommendations on drug regimens to be used in the treatment of ZVL.